MUC16 and ovarian carcinoma: From our previous study, we identified SIK3 as a novel ovarian TAA that is highly and preferentially expressed in ovarian cancer but not in benign gynecologic diseases, i.e., adenomyosis or endometriosis, with elevated CA125 levels.